Intellia Therapeutics, Inc.(NASDAQ : NTLA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-0.46%||8.65||0.7%||$604.67m|
|GILD||Gilead Sciences, Inc.||-0.70%||71.19||1.0%||$455.28m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.18%||638.90||2.7%||$418.56m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.80%||183.61||1.9%||$245.25m|
|ISEE||IVERIC bio, Inc.||0.86%||16.37||0.0%||$193.25m|
|DVAX||Dynavax Technologies Corp.||1.17%||19.83||5.7%||$156.65m|
|LIFE||aTyr Pharma, Inc.||-17.87%||10.25||2.1%||$156.36m|
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.